Use of insulin glargine U300 to improve glycaemic control in type 2 diabetes
28 Aug 2026
byDr. David Tak-Wai Lui, Clinical Assistant Professor , Division of Endocrinology and Metabolism, Department of Medicine, The University of Hong Kong, Hong Kong
A
66-year-old female with a 20-year history of type 2 diabetes (T2D) presented
with suboptimal glycaemic control. Her comorbidities included minor coronary
artery disease, metabolic dysfunction–associated steatotic liver disease
(MASLD), and chronic hepatitis B (HBV) carrier status. She had a body mass
index (BMI) of 34.7 kg/m2, blood pressure (BP) of 132/56 mm Hg, and
LDL-cholesterol (LDL-C) level of 1.5 mmol/L.
